Sosinsky, Alona
Ambrose, John
Cross, William http://orcid.org/0000-0002-4794-8777
Turnbull, Clare
Henderson, Shirley
Jones, Louise
Hamblin, Angela
Arumugam, Prabhu
Chan, Georgia
Chubb, Daniel
Noyvert, Boris
Mitchell, Jonathan
Walker, Susan
Bowman, Katy
Pasko, Dorota
Buongermino Pereira, Marianna http://orcid.org/0000-0003-3450-949X
Volkova, Nadezda
Rueda-Martin, Antonio
Perez-Gil, Daniel
Lopez, Javier
Pullinger, John http://orcid.org/0000-0001-9357-1184
Siddiq, Afshan
Zainy, Tala
Choudhury, Tasnim
Yavorska, Olena
Fowler, Tom
Bentley, David
Kingsley, Clare
Hing, Sandra
Deans, Zandra
Rendon, Augusto http://orcid.org/0000-0001-8994-0039
Hill, Sue
Caulfield, Mark http://orcid.org/0000-0001-9295-3594
Murugaesu, Nirupa http://orcid.org/0000-0002-5005-7908
Funding for this research was provided by:
Cancer Research UK (C1298/A8362, C17422/A25154.)
DH | National Institute for Health Research (Barts Biomedical Research Centre)
Article History
Received: 19 December 2022
Accepted: 2 November 2023
First Online: 11 January 2024
Competing interests
: Genomics England is a company wholly owned by the UK DHSC and was created in 2013 to introduce WGS into healthcare in conjunction with NHS England. All authors affiliated with Genomics England (A. Sosinsky, J.A., C.T., S. Henderson, L.J., A.H., P.A., G.C., J.M., S.W., K.B., D.P., M.B.P., N.V., A.R.-M., D.P.-G., J.L., J.P., A. Siddiq, T.Z., T.C., O.Y., T.F., A.R., M.C. and N.M.) are, or were, salaried by or seconded to Genomics England. D.B. and C.K. are full-time employees and shareholders of Illumina. A.H. has received speaker fees from Gilead, Roche, Pfizer, Jazz, AbbVie, Incyte and Astellas. N.M. has provided consulting and advisory support for Pfizer, Guardant, Seagen and Janssen, and received speaker fees from Novartis, Pfizer and Servier outside of the submitted work. The remaining authors declare no competing interests.